The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC)

Paracha, Norman; Davies, Andrew; Latimer, Nicholas; Parker, Christopher; Mealing, Stuart; Scott, David; Padhiar, Arnie; Schulpher, Mark; Wang, Qing

The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC)

journal contribution

posted on 2024-09-20, 03:10 authored by Norman Paracha, Andrew Davies, Nicholas Latimer, Christopher Parker, Stuart Mealing, David ScottDavid Scott, Arnie Padhiar, Mark Schulpher, Qing Wang

The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC)

History

Location

IL, Chicago

Language

English

Publication classification

E3.1 Extract of paper

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume

31

ISSN

0732-183X

eISSN

1527-7755

Issue

15

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology

The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC)

History

Location

Language

Publication classification

Journal

Volume

ISSN

eISSN

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports